PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17123666-2 2008 One of the most robust assays for SCN melatonin receptor activation in mice is the inhibition of PACAP-induced phosphorylation of the transcription factor Ca(2+)/cAMP responsive element binding protein (CREB). Cyclic AMP 162-166 adenylate cyclase activating polypeptide 1 Mus musculus 97-102 18000164-6 2008 In contrast, neutralizing monoclonal anti-PACAP (PP1A4) or anti-VPAC1 (23A11) antibodies inhibit cAMP formation and stimulate megakaryopoiesis in a thrombopoietin-independent manner. Cyclic AMP 97-101 adenylate cyclase activating polypeptide 1 Mus musculus 42-47 17596563-9 2007 The MEK inhibitor, U0126, and the PKA inhibitors, H89 and cAMP-dependent protein kinase peptide inhibitor (PKI), completely inhibited MAPK3/1 activation by either ADCYAP1 or CPT-cAMP. Cyclic AMP 58-62 adenylate cyclase activating polypeptide 1 Mus musculus 163-170 17596563-10 2007 Using luciferase reporter constructs containing cis-elements, the cAMP response element (Cre) promoter was stimulated about 4-fold by ADCYAP1. Cyclic AMP 66-70 adenylate cyclase activating polypeptide 1 Mus musculus 134-141 17596563-1 2007 Adenylate cyclase-activating polypeptide 1 (ADCYAP1) binds both Gs- and Gq-coupled receptors and stimulates adenylate cyclase/cAMP and protein kinase C/mitogen-activated protein kinase 3/1 (MAPK3/1) signaling pathways in pituitary gonadotrophs. Cyclic AMP 126-130 adenylate cyclase activating polypeptide 1 Mus musculus 0-42 17383102-8 2007 Inhibition of the cAMP signaling and the activity of phospholipase C significantly reduced the effects of exogenous PACAP on granule cell migration. Cyclic AMP 18-22 adenylate cyclase activating polypeptide 1 Mus musculus 116-121 17596563-1 2007 Adenylate cyclase-activating polypeptide 1 (ADCYAP1) binds both Gs- and Gq-coupled receptors and stimulates adenylate cyclase/cAMP and protein kinase C/mitogen-activated protein kinase 3/1 (MAPK3/1) signaling pathways in pituitary gonadotrophs. Cyclic AMP 126-130 adenylate cyclase activating polypeptide 1 Mus musculus 44-51 17596563-3 2007 ADCYAP1 increased intracellular cAMP accumulation up to 19-fold in LbetaT2 cells. Cyclic AMP 32-36 adenylate cyclase activating polypeptide 1 Mus musculus 0-7 17561835-9 2007 Autoradiographic studies revealed no difference in PACAP binding site distributions and PACAP was effective at stimulating cAMP production in both wild-type and PACAP-/- cultured granule cells. Cyclic AMP 123-127 adenylate cyclase activating polypeptide 1 Mus musculus 88-93 17561835-9 2007 Autoradiographic studies revealed no difference in PACAP binding site distributions and PACAP was effective at stimulating cAMP production in both wild-type and PACAP-/- cultured granule cells. Cyclic AMP 123-127 adenylate cyclase activating polypeptide 1 Mus musculus 88-93 16888195-1 2006 The effects and respective influence of pituitary adenylate cyclase-activating polypeptide (PACAP) and gonadotropin-releasing hormone (GnRH) on cyclic AMP (cAMP) production in pituitary gonadotropes were analyzed using the LbetaT2 cell line. Cyclic AMP 144-154 adenylate cyclase activating polypeptide 1 Mus musculus 40-98 17213203-3 2007 Expression of the bPAC1hop receptor in NG108-15 cells, which lack endogenous PAC1 receptors, reconstituted high affinity PACAP binding and PACAP-dependent elevation of both cAMP and intracellular Ca2+ concentrations ([Ca2+]i). Cyclic AMP 173-177 adenylate cyclase activating polypeptide 1 Mus musculus 121-126 17213203-3 2007 Expression of the bPAC1hop receptor in NG108-15 cells, which lack endogenous PAC1 receptors, reconstituted high affinity PACAP binding and PACAP-dependent elevation of both cAMP and intracellular Ca2+ concentrations ([Ca2+]i). Cyclic AMP 173-177 adenylate cyclase activating polypeptide 1 Mus musculus 139-144 17213203-4 2007 Removal of the hop domain and expression of this receptor (bPAC1null) in NG108-15 cells reconstituted high affinity PACAP binding and PACAP-dependent cAMP generation but without a corresponding [Ca2+]i elevation. Cyclic AMP 150-154 adenylate cyclase activating polypeptide 1 Mus musculus 134-139 16959402-8 2006 PACAP increased intracellular cAMP more than GnRH did in LbetaT2 cells, and the elevation of cAMP was strongly inhibited in the presence of various dopamine D(2) agonists. Cyclic AMP 30-34 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 16959402-8 2006 PACAP increased intracellular cAMP more than GnRH did in LbetaT2 cells, and the elevation of cAMP was strongly inhibited in the presence of various dopamine D(2) agonists. Cyclic AMP 93-97 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 17115416-2 2007 It has been well established that the PACAP/PAC1 system induces differentiation of neural progenitor cells (NPCs) through the Gs-mediated cAMP-dependent signaling pathway. Cyclic AMP 138-142 adenylate cyclase activating polypeptide 1 Mus musculus 38-43 16888195-4 2006 Despite its positive coupling to cAMP pathway, GnRH counteracted PACAP induction of cAMP and this effect was mimicked by the PKC activator phorbol 12-myristate 13-acetate (PMA). Cyclic AMP 84-88 adenylate cyclase activating polypeptide 1 Mus musculus 65-70 16888195-5 2006 The data reveal major differences in the mechanisms by which PACAP and GnRH activate cAMP/PKA pathway in LbetaT2 cells and suggest that PKC activation serves GnRH not only to increase cAMP but also to counteract the PACAP stimulation of this signaling pathway. Cyclic AMP 85-89 adenylate cyclase activating polypeptide 1 Mus musculus 61-66 16888195-5 2006 The data reveal major differences in the mechanisms by which PACAP and GnRH activate cAMP/PKA pathway in LbetaT2 cells and suggest that PKC activation serves GnRH not only to increase cAMP but also to counteract the PACAP stimulation of this signaling pathway. Cyclic AMP 184-188 adenylate cyclase activating polypeptide 1 Mus musculus 61-66 14519095-2 2003 In rat pituitary cells and mouse alphaT3-1 precursor gonadotrophs, the human alphaGSU promoter is strongly responsive to activators of the adenylyl cyclase/cAMP pathway, such as the hypothalamic releasing hormone, pituitary adenylate cyclase-activating polypeptide (PACAP) and forskolin (an adenylyl cyclase activator). Cyclic AMP 156-160 adenylate cyclase activating polypeptide 1 Mus musculus 266-271 15194876-3 2004 The inhibitory effect of PACAP appeared to be mediated through an increase in intracellular cAMP. Cyclic AMP 92-96 adenylate cyclase activating polypeptide 1 Mus musculus 25-30 16426762-6 2006 The PACAP-induced reduction of Kv4.1 and Kv4.2 expression was completely blocked by inhibiting the phospholipase C (PLC) pathway but was still significantly downregulated by PACAP when the cyclic AMP pathway was inhibited. Cyclic AMP 189-199 adenylate cyclase activating polypeptide 1 Mus musculus 4-9 16426762-6 2006 The PACAP-induced reduction of Kv4.1 and Kv4.2 expression was completely blocked by inhibiting the phospholipase C (PLC) pathway but was still significantly downregulated by PACAP when the cyclic AMP pathway was inhibited. Cyclic AMP 189-199 adenylate cyclase activating polypeptide 1 Mus musculus 174-179 11931347-4 2002 PACAP-27 caused cAMP elevation in NIH/3T3 cells transfected with PAC1 receptors and the increase cAMP caused by pituitary adenylated cyclase (PACAP) was inhibited by (SN)VIPhyb. Cyclic AMP 97-101 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 11931347-4 2002 PACAP-27 caused cAMP elevation in NIH/3T3 cells transfected with PAC1 receptors and the increase cAMP caused by pituitary adenylated cyclase (PACAP) was inhibited by (SN)VIPhyb. Cyclic AMP 16-20 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 11931347-4 2002 PACAP-27 caused cAMP elevation in NIH/3T3 cells transfected with PAC1 receptors and the increase cAMP caused by pituitary adenylated cyclase (PACAP) was inhibited by (SN)VIPhyb. Cyclic AMP 16-20 adenylate cyclase activating polypeptide 1 Mus musculus 142-147 12297539-10 2002 Cyclic AMP accumulation in alphaT3-1 cells was increased by treatment with PACAP, and quinpirol inhibited this effect. Cyclic AMP 0-10 adenylate cyclase activating polypeptide 1 Mus musculus 75-80 12090758-6 2002 By using selective PKA and PKC inhibitors and cAMP mimicked agents, we demonstrated a cAMP-dependent signalling pathway for the inhibitory effect of VIP/PACAP on MIP-1alpha production, although a minor non-mediated cAMP pathway was also involved. Cyclic AMP 46-50 adenylate cyclase activating polypeptide 1 Mus musculus 153-158 12090758-6 2002 By using selective PKA and PKC inhibitors and cAMP mimicked agents, we demonstrated a cAMP-dependent signalling pathway for the inhibitory effect of VIP/PACAP on MIP-1alpha production, although a minor non-mediated cAMP pathway was also involved. Cyclic AMP 86-90 adenylate cyclase activating polypeptide 1 Mus musculus 153-158 12090758-6 2002 By using selective PKA and PKC inhibitors and cAMP mimicked agents, we demonstrated a cAMP-dependent signalling pathway for the inhibitory effect of VIP/PACAP on MIP-1alpha production, although a minor non-mediated cAMP pathway was also involved. Cyclic AMP 86-90 adenylate cyclase activating polypeptide 1 Mus musculus 153-158 11931347-4 2002 PACAP-27 caused cAMP elevation in NIH/3T3 cells transfected with PAC1 receptors and the increase cAMP caused by pituitary adenylated cyclase (PACAP) was inhibited by (SN)VIPhyb. Cyclic AMP 97-101 adenylate cyclase activating polypeptide 1 Mus musculus 142-147 11579206-3 2001 PACAP is a neuropeptide that causes accumulation of cAMP in a number of tissues and affects the secretion of other hormones, vasodilation, neural and immune functions, as well as the cell cycle. Cyclic AMP 52-56 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 11412341-6 2001 These results strongly implicated the involvement of an adenylate cyclase/cAMP/PKA pathway in PACAP-stimulated GTH-II release. Cyclic AMP 74-78 adenylate cyclase activating polypeptide 1 Mus musculus 94-99 11412341-12 2001 These data suggest that PACAP and its cAMP-dependent signalling mechanisms provide an alternate stimulatory input to goldfish gonadotropes and may influence the effectiveness of the major neuroendocrine control exerted by the PKC-dependent GnRH signalling pathway. Cyclic AMP 38-42 adenylate cyclase activating polypeptide 1 Mus musculus 24-29 11145597-3 2001 By analyzing the cAMP response, the rank order of response observed was PACAP 38 > PACAP 27 > helodermin > VIP > helospectin > glucagon > PHI >>> secretin. Cyclic AMP 17-21 adenylate cyclase activating polypeptide 1 Mus musculus 72-77 11145597-3 2001 By analyzing the cAMP response, the rank order of response observed was PACAP 38 > PACAP 27 > helodermin > VIP > helospectin > glucagon > PHI >>> secretin. Cyclic AMP 17-21 adenylate cyclase activating polypeptide 1 Mus musculus 86-91 11145597-4 2001 The VIP-2R/PACAP-R antagonist, PACAP 6-38, inhibited both VIP- and PACAP-stimulated cAMP formation. Cyclic AMP 84-88 adenylate cyclase activating polypeptide 1 Mus musculus 11-16 11145597-4 2001 The VIP-2R/PACAP-R antagonist, PACAP 6-38, inhibited both VIP- and PACAP-stimulated cAMP formation. Cyclic AMP 84-88 adenylate cyclase activating polypeptide 1 Mus musculus 31-36 11145597-4 2001 The VIP-2R/PACAP-R antagonist, PACAP 6-38, inhibited both VIP- and PACAP-stimulated cAMP formation. Cyclic AMP 84-88 adenylate cyclase activating polypeptide 1 Mus musculus 31-36 10808055-5 2000 The effect of VIP is mediated primarily through the cAMP pathway, whereas PACAP activates both the cAMP and the protein kinase C pathway. Cyclic AMP 99-103 adenylate cyclase activating polypeptide 1 Mus musculus 74-79 11193883-6 2000 VIP/PACAP binding to VPAC1 induces both a cAMP-dependent and a cAMP-independent pathways that regulate cytokine and NO production at the transcriptional level. Cyclic AMP 42-46 adenylate cyclase activating polypeptide 1 Mus musculus 4-9 10884023-6 2000 Thus, melatonin modulates PACAP-mediated retinal stimuli for clock entrainment primarily via the Mel1a melatonin receptor through molecular interaction within the cAMP-signalling pathway. Cyclic AMP 163-167 adenylate cyclase activating polypeptide 1 Mus musculus 26-31 10698199-2 2000 The PACAP messenger RNA (mRNA) and protein is expressed at high levels in the germ cells of the testis, where it locally activates cAMP-coupled receptors located in the somatic Sertoli cells. Cyclic AMP 131-135 adenylate cyclase activating polypeptide 1 Mus musculus 4-9 11193883-6 2000 VIP/PACAP binding to VPAC1 induces both a cAMP-dependent and a cAMP-independent pathways that regulate cytokine and NO production at the transcriptional level. Cyclic AMP 63-67 adenylate cyclase activating polypeptide 1 Mus musculus 4-9 11193883-9 2000 Whereas the inhibition of IRF-1 and CRE-binding complexes seems to be mediated through the cAMP-dependent pathway, VIP/PACAP inhibition of NFkB nuclear translocation is mediated through a reduction in IkB alpha degradation mediated by the cAMP-independent pathway. Cyclic AMP 239-243 adenylate cyclase activating polypeptide 1 Mus musculus 119-124 9523559-3 1998 Prolonged incubation of cells with PACAP failed to down-regulate the density and affinity of membrane binding sites and caused opposite changes in messenger systems: PACAP-stimulated cyclic AMP accumulation was attenuated in a time- and dose-dependent fashion (t(1/2) = 6.7 h and IC50 = 0.1 nM), whereas phosphoinositide turnover was overstimulated. Cyclic AMP 183-193 adenylate cyclase activating polypeptide 1 Mus musculus 35-40 9528956-5 1998 Transfection of an alpha-promoter construct containing a mutant cAMP response element (CRE) suggested that the CRE region is involved in PACAP and VIP responsiveness, with stimulatory effects on the mutant construct by PACAP (11.1-fold) and VIP (7.6-fold) being significantly (P < 0.001) reduced, compared with their stimulatory effects (PACAP: 25.6-fold, VIP: 23.1-fold) on the native alpha-promoter. Cyclic AMP 64-68 adenylate cyclase activating polypeptide 1 Mus musculus 137-142 9528956-5 1998 Transfection of an alpha-promoter construct containing a mutant cAMP response element (CRE) suggested that the CRE region is involved in PACAP and VIP responsiveness, with stimulatory effects on the mutant construct by PACAP (11.1-fold) and VIP (7.6-fold) being significantly (P < 0.001) reduced, compared with their stimulatory effects (PACAP: 25.6-fold, VIP: 23.1-fold) on the native alpha-promoter. Cyclic AMP 64-68 adenylate cyclase activating polypeptide 1 Mus musculus 219-224 9528956-5 1998 Transfection of an alpha-promoter construct containing a mutant cAMP response element (CRE) suggested that the CRE region is involved in PACAP and VIP responsiveness, with stimulatory effects on the mutant construct by PACAP (11.1-fold) and VIP (7.6-fold) being significantly (P < 0.001) reduced, compared with their stimulatory effects (PACAP: 25.6-fold, VIP: 23.1-fold) on the native alpha-promoter. Cyclic AMP 64-68 adenylate cyclase activating polypeptide 1 Mus musculus 219-224 9973433-7 1999 Electromobility shift assays show that VIP/PACAP induce an increase in nuclear cAMP response element (CRE)-binding complexes, with CRE binding protein as the major active component. Cyclic AMP 79-83 adenylate cyclase activating polypeptide 1 Mus musculus 43-48 9689127-4 1998 PACAP potently increased cAMP levels more than 20-fold in cultured E10.5 hindbrain neuroepithelial cells, suggesting that PACAP activates protein kinase A (PKA) in the neural tube and might act in the process of patterning. Cyclic AMP 25-29 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 9689127-4 1998 PACAP potently increased cAMP levels more than 20-fold in cultured E10.5 hindbrain neuroepithelial cells, suggesting that PACAP activates protein kinase A (PKA) in the neural tube and might act in the process of patterning. Cyclic AMP 25-29 adenylate cyclase activating polypeptide 1 Mus musculus 122-127 9689127-6 1998 PACAP is thus an early inducer of cAMP levels in the embryo and may act in the neural tube during patterning to control cell proliferation and gene expression. Cyclic AMP 34-38 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 9523559-8 1998 They demonstrate that prolonged exposure of CATH.a cells to PACAP results in the desensitization of the cyclic AMP pathway and superinduction of the inositol phosphate signal, through protein neosynthesis and cyclic AMP-dependent protein kinase activation. Cyclic AMP 104-114 adenylate cyclase activating polypeptide 1 Mus musculus 60-65 9523559-9 1998 At the same time, they show that desensitization of cyclic AMP signaling not only fails to hamper, but actually amplifies PACAP-stimulated CREB-regulated transcription. Cyclic AMP 52-62 adenylate cyclase activating polypeptide 1 Mus musculus 122-127 9523559-3 1998 Prolonged incubation of cells with PACAP failed to down-regulate the density and affinity of membrane binding sites and caused opposite changes in messenger systems: PACAP-stimulated cyclic AMP accumulation was attenuated in a time- and dose-dependent fashion (t(1/2) = 6.7 h and IC50 = 0.1 nM), whereas phosphoinositide turnover was overstimulated. Cyclic AMP 183-193 adenylate cyclase activating polypeptide 1 Mus musculus 166-171 9605511-6 1998 The pattern of alpha-subunit stimulation by cAMP closely paralleled that of PACAP. Cyclic AMP 44-48 adenylate cyclase activating polypeptide 1 Mus musculus 76-81 9322946-6 1997 Furthermore, in alphaT3-1 cells PACAP activation of the follistatin promoter appears to be via the cAMP-dependent protein kinase A pathway. Cyclic AMP 99-103 adenylate cyclase activating polypeptide 1 Mus musculus 32-37 9468014-2 1997 In the gonadotroph-derived alphaT3-1 cell line, PACAP acts via PVR1 receptors to stimulate adenylyl cyclase and phosphoinositidase C. PACAP-stimulated cAMP accumulation is inhibited by protein kinase C-activating phorbol esters in these cells and the current work was undertaken primarily to establish whether it is also subject to homologous regulation. Cyclic AMP 151-155 adenylate cyclase activating polypeptide 1 Mus musculus 48-53 9468014-2 1997 In the gonadotroph-derived alphaT3-1 cell line, PACAP acts via PVR1 receptors to stimulate adenylyl cyclase and phosphoinositidase C. PACAP-stimulated cAMP accumulation is inhibited by protein kinase C-activating phorbol esters in these cells and the current work was undertaken primarily to establish whether it is also subject to homologous regulation. Cyclic AMP 151-155 adenylate cyclase activating polypeptide 1 Mus musculus 134-139 9468014-9 1997 In chronic desensitization studies, pre-treatment for 6 h with PACAP27 caused a dose-dependent (IC50 approximately 10 nM) reduction of PACAP-stimulated cAMP accumulation and down regulated cell surface PVR1 receptors (to approximately 50%). Cyclic AMP 152-156 adenylate cyclase activating polypeptide 1 Mus musculus 63-68 9468014-11 1997 Chronic desensitization of PACAP-stimulated cAMP accumulation and down-regulation of cell surface PVR-1 receptors also occurs in these cells although the receptor loss may not entirely explain the observed desensitization. Cyclic AMP 44-48 adenylate cyclase activating polypeptide 1 Mus musculus 27-32 9084443-7 1997 We conclude that CATH.a cells do express functional PACAP type I receptors, the activation of which impinges on TH and c-fos transcription according to a process that is primarily dependent on the cyclic AMP-PKA pathway. Cyclic AMP 197-207 adenylate cyclase activating polypeptide 1 Mus musculus 52-57 9112389-5 1997 PACAP stimulated POMC 5" promoter activity as well as cAMP generation and ACTH secretion in a dose- and time-dependent manner, with the maximal effect being observed 3 h after the start of incubation. Cyclic AMP 54-58 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 9179866-2 1997 Recently, PACAP has been shown to stimulate cAMP in osteoblast-like cells and mouse calvarian bones. Cyclic AMP 44-48 adenylate cyclase activating polypeptide 1 Mus musculus 10-15 7585525-6 1995 PACAP-27 elevated cAMP in a dose-dependent manner, and the increase in cAMP caused by PACAP was reversed by PACAP(6-38). Cyclic AMP 18-22 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 8843778-3 1996 We determined the effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on CCK secretion and cAMP production and its interaction with other CCK secretagogues in STC-1 cells. Cyclic AMP 108-112 adenylate cyclase activating polypeptide 1 Mus musculus 28-78 8843778-7 1996 Both forms of PACAP and VIP stimulated a transient but not significant increase in the cellular cAMP level. Cyclic AMP 96-100 adenylate cyclase activating polypeptide 1 Mus musculus 14-19 8666779-6 1996 The fact that VIP, PACAP-38, and forskolin, all known cAMP inducers, also inhibit IL-10 production, suggests the participation of cAMP in signal transduction. Cyclic AMP 54-58 adenylate cyclase activating polypeptide 1 Mus musculus 19-24 8993397-2 1996 In recent years an increasing number of examples of functional interactions occurring between the PIC and adenylyl cyclase signaling pathways in gonadotropes have been described, and the discovery that these cells are targets for PACAP has provided a physiological context for earlier work on gonadotrope regulation by cyclic AMP. Cyclic AMP 319-329 adenylate cyclase activating polypeptide 1 Mus musculus 230-235 8752106-10 1996 These results show that (a) PACAP27 and PACAP38 stimulate cAMP accumulation and increase [Ca2+]i through the type I PACAP receptors in N1E-115 cells, (b) ionomycin enhances cAMP accumulation by all three peptides, and (c) activation of protein kinase C has a dose-dependent stimulatory or inhibitory effect on the PACAP38- or PACAP27-stimulated cAMP accumulation. Cyclic AMP 58-62 adenylate cyclase activating polypeptide 1 Mus musculus 28-33 8752106-10 1996 These results show that (a) PACAP27 and PACAP38 stimulate cAMP accumulation and increase [Ca2+]i through the type I PACAP receptors in N1E-115 cells, (b) ionomycin enhances cAMP accumulation by all three peptides, and (c) activation of protein kinase C has a dose-dependent stimulatory or inhibitory effect on the PACAP38- or PACAP27-stimulated cAMP accumulation. Cyclic AMP 173-177 adenylate cyclase activating polypeptide 1 Mus musculus 28-33 8752106-10 1996 These results show that (a) PACAP27 and PACAP38 stimulate cAMP accumulation and increase [Ca2+]i through the type I PACAP receptors in N1E-115 cells, (b) ionomycin enhances cAMP accumulation by all three peptides, and (c) activation of protein kinase C has a dose-dependent stimulatory or inhibitory effect on the PACAP38- or PACAP27-stimulated cAMP accumulation. Cyclic AMP 173-177 adenylate cyclase activating polypeptide 1 Mus musculus 28-33 8666779-6 1996 The fact that VIP, PACAP-38, and forskolin, all known cAMP inducers, also inhibit IL-10 production, suggests the participation of cAMP in signal transduction. Cyclic AMP 130-134 adenylate cyclase activating polypeptide 1 Mus musculus 19-24 7585525-6 1995 PACAP-27 elevated cAMP in a dose-dependent manner, and the increase in cAMP caused by PACAP was reversed by PACAP(6-38). Cyclic AMP 71-75 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 7845539-2 1994 Treatment of these cells with PACAP 27/38 led to a dose-dependent increase in cAMP content and ACTH accumulation in the medium with an apparent ED50 value close to 10(-9) M. The genomic effects of PACAP were first investigated by using a reporter gene containing a cAMP responsive element (CRE: TGACGTCA) PACAP 27/38 stimulate transcription from this construction and the effect is further increased when cells are cotreated with the phosphodiesterase inhibitor rolipram. Cyclic AMP 78-82 adenylate cyclase activating polypeptide 1 Mus musculus 30-35 8674819-10 1995 These findings are consistent with the proposal that PACAP contributes to the high levels of alpha-subunit protein characteristic of the pituitary by activating Type I receptors and stimulating alpha-subunit gene transcription in part by the cAMP/PKA pathway. Cyclic AMP 242-246 adenylate cyclase activating polypeptide 1 Mus musculus 53-58 7589782-7 1995 Co-incubation of AtT-20 cells with Rolipram along with inhibitors of type I (but not of type III) PDEs, enhanced cAMP formation elicited by PACAP to a level significantly higher than that induced by CRF. Cyclic AMP 113-117 adenylate cyclase activating polypeptide 1 Mus musculus 140-145 7845539-2 1994 Treatment of these cells with PACAP 27/38 led to a dose-dependent increase in cAMP content and ACTH accumulation in the medium with an apparent ED50 value close to 10(-9) M. The genomic effects of PACAP were first investigated by using a reporter gene containing a cAMP responsive element (CRE: TGACGTCA) PACAP 27/38 stimulate transcription from this construction and the effect is further increased when cells are cotreated with the phosphodiesterase inhibitor rolipram. Cyclic AMP 78-82 adenylate cyclase activating polypeptide 1 Mus musculus 197-202 7845539-2 1994 Treatment of these cells with PACAP 27/38 led to a dose-dependent increase in cAMP content and ACTH accumulation in the medium with an apparent ED50 value close to 10(-9) M. The genomic effects of PACAP were first investigated by using a reporter gene containing a cAMP responsive element (CRE: TGACGTCA) PACAP 27/38 stimulate transcription from this construction and the effect is further increased when cells are cotreated with the phosphodiesterase inhibitor rolipram. Cyclic AMP 78-82 adenylate cyclase activating polypeptide 1 Mus musculus 197-202 7845539-2 1994 Treatment of these cells with PACAP 27/38 led to a dose-dependent increase in cAMP content and ACTH accumulation in the medium with an apparent ED50 value close to 10(-9) M. The genomic effects of PACAP were first investigated by using a reporter gene containing a cAMP responsive element (CRE: TGACGTCA) PACAP 27/38 stimulate transcription from this construction and the effect is further increased when cells are cotreated with the phosphodiesterase inhibitor rolipram. Cyclic AMP 265-269 adenylate cyclase activating polypeptide 1 Mus musculus 30-35 1332141-0 1992 Neuropeptides of the vasoactive intestinal peptide/helodermin/pituitary adenylate cyclase activating peptide family elevate plasma cAMP in mice: comparison with a range of other regulatory peptides. Cyclic AMP 131-135 adenylate cyclase activating polypeptide 1 Mus musculus 62-108 7515005-1 1994 Pituitary adenylate cyclase-activating polypeptide (PACAP) acts via type I receptors in the pituitary to stimulate cAMP production. Cyclic AMP 115-119 adenylate cyclase activating polypeptide 1 Mus musculus 0-50 7515005-1 1994 Pituitary adenylate cyclase-activating polypeptide (PACAP) acts via type I receptors in the pituitary to stimulate cAMP production. Cyclic AMP 115-119 adenylate cyclase activating polypeptide 1 Mus musculus 52-57 7515005-3 1994 Here we have explored the influence of GnRH on PACAP action in alpha T3-1 cells and show that PACAP38-stimulated cAMP production is inhibited by GnRH in both the presence and the absence of a phosphodiesterase inhibitor. Cyclic AMP 113-117 adenylate cyclase activating polypeptide 1 Mus musculus 47-52 7914821-5 1994 Also, helospectin I, PACAP 27, and the C-terminally extended PACAP 38 stimulated cAMP accumulation in the mouse calvariae. Cyclic AMP 81-85 adenylate cyclase activating polypeptide 1 Mus musculus 61-66 7914821-7 1994 Helodermin, helospectin I, PACAP 27, and PACAP 38, at concentrations of 1 mumol/liter, stimulated cAMP accumulation in enzymatically isolated mouse calvarial bone cells. Cyclic AMP 98-102 adenylate cyclase activating polypeptide 1 Mus musculus 27-32 7914821-7 1994 Helodermin, helospectin I, PACAP 27, and PACAP 38, at concentrations of 1 mumol/liter, stimulated cAMP accumulation in enzymatically isolated mouse calvarial bone cells. Cyclic AMP 98-102 adenylate cyclase activating polypeptide 1 Mus musculus 41-46 8102056-1 1993 PACAP 27 and 38 (27 and 38 amino acids, respectively) increased rapidly cAMP production in porcine thyroid cells in vitro. Cyclic AMP 72-76 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 7912096-0 1994 Pituitary adenylate cyclase-activating polypeptide induces cAMP production independently from vasoactive intestinal polypeptide in osteoblast-like cells. Cyclic AMP 59-63 adenylate cyclase activating polypeptide 1 Mus musculus 0-50 7912096-4 1994 PACAP stimulated cAMP accumulation in a dose-dependent manner in the range between 0.1 nM and 0.1 microM in these cells. Cyclic AMP 17-21 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 7912096-6 1994 The effect of PACAP on cAMP accumulation (EC50 = 3 nM) was more potent than that of VIP (EC50 = 30 nM). Cyclic AMP 23-27 adenylate cyclase activating polypeptide 1 Mus musculus 14-19 7912096-7 1994 The cAMP accumulation stimulated by a combination of PACAP (3 nM) and VIP (30 nM) was additive. Cyclic AMP 4-8 adenylate cyclase activating polypeptide 1 Mus musculus 53-58 7912096-10 1994 These results strongly suggest that PACAP stimulates cAMP production via an independent binding site from VIP in osteoblast-like MC3T3-E1 cells and that PACAP has no effect on the activation of protein kinase C nor the intracellular Ca2+ mobilization in these cells. Cyclic AMP 53-57 adenylate cyclase activating polypeptide 1 Mus musculus 36-41 8404665-4 1993 Both the 27- and 38-amino acid forms of PACAP (PACAP-27 and PACAP-38) and vasoactive intestinal peptide (VIP) increased the levels of cAMP in TtT/GF cells in a similar dose-dependent manner. Cyclic AMP 134-138 adenylate cyclase activating polypeptide 1 Mus musculus 40-45 8404665-4 1993 Both the 27- and 38-amino acid forms of PACAP (PACAP-27 and PACAP-38) and vasoactive intestinal peptide (VIP) increased the levels of cAMP in TtT/GF cells in a similar dose-dependent manner. Cyclic AMP 134-138 adenylate cyclase activating polypeptide 1 Mus musculus 47-52 8404665-4 1993 Both the 27- and 38-amino acid forms of PACAP (PACAP-27 and PACAP-38) and vasoactive intestinal peptide (VIP) increased the levels of cAMP in TtT/GF cells in a similar dose-dependent manner. Cyclic AMP 134-138 adenylate cyclase activating polypeptide 1 Mus musculus 60-68 1280235-0 1992 Pituitary adenylate cyclase polypeptide (PACAP) stimulates cyclic AMP formation in pituitary fibroblasts and 3T3 tumor fibroblasts: lack of enhancement by protein kinase C activation. Cyclic AMP 59-69 adenylate cyclase activating polypeptide 1 Mus musculus 0-39 1332141-5 1992 Repeated injections of PACAP-27 every 30 min caused a progressive reduction in the plasma cAMP response (measured 5 min after each injection). Cyclic AMP 90-94 adenylate cyclase activating polypeptide 1 Mus musculus 23-28 1332141-8 1992 Combined treatment with PACAP-27 and a threshold dose of rolipram resulted in an exaggerated plasma cAMP response. Cyclic AMP 100-104 adenylate cyclase activating polypeptide 1 Mus musculus 24-29 1332141-12 1992 PACAP-27 stimulated cAMP efflux from the isolated rat tail vein. Cyclic AMP 20-24 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 9250719-3 1997 PACAPhybrid antagonized the ability of PACAP-27 to elevate cAMP regardless of the PACAP-R SV used. Cyclic AMP 59-63 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 9250719-3 1997 PACAPhybrid antagonized the ability of PACAP-27 to elevate cAMP regardless of the PACAP-R SV used. Cyclic AMP 59-63 adenylate cyclase activating polypeptide 1 Mus musculus 39-44 29363578-6 2018 PA-8 and PA-9 also dose dependently inhibited PACAP-induced cAMP elevation with an IC50 of 2.0 and 5.6 nM, respectively. Cyclic AMP 60-64 adenylate cyclase activating polypeptide 1 Mus musculus 46-51 31034837-7 2019 In the gonadotropes, PACAP activates primarily Galphas and increases concentration of cAMP, while GnRH primarily functions via Galphaq and increases calcium concentration. Cyclic AMP 86-90 adenylate cyclase activating polypeptide 1 Mus musculus 21-26 31034837-10 2019 We determined that FSHbeta induction by PACAP requires functional EPAC, a cAMP sensor protein that serves as a guanine exchange factors for small G proteins that then bridges cAMP signaling to MAPK pathway. Cyclic AMP 74-78 adenylate cyclase activating polypeptide 1 Mus musculus 40-45 31034837-10 2019 We determined that FSHbeta induction by PACAP requires functional EPAC, a cAMP sensor protein that serves as a guanine exchange factors for small G proteins that then bridges cAMP signaling to MAPK pathway. Cyclic AMP 175-179 adenylate cyclase activating polypeptide 1 Mus musculus 40-45 31034837-12 2019 Therefore, PACAP-induced cAMP pathway leads to MAPK activation that stimulates cFOS induction, to induce the expression of FSHbeta subunit and increase FSH concentration. Cyclic AMP 25-29 adenylate cyclase activating polypeptide 1 Mus musculus 11-16 31006726-3 2019 Pituitary adenylate cyclase-activating polypeptide (PACAP) also regulates GnRH responsiveness in gonadotropes through the PACAP receptor, which activates the Gs/cAMP signaling pathway. Cyclic AMP 161-165 adenylate cyclase activating polypeptide 1 Mus musculus 0-50 31006726-3 2019 Pituitary adenylate cyclase-activating polypeptide (PACAP) also regulates GnRH responsiveness in gonadotropes through the PACAP receptor, which activates the Gs/cAMP signaling pathway. Cyclic AMP 161-165 adenylate cyclase activating polypeptide 1 Mus musculus 52-57 27345595-4 2016 PACAP eye drops stimulate tear secretion and increase cAMP and phosphorylated (p)-protein kinase A levels in the infraorbital lacrimal glands that could be inhibited by pre-treatment with a PAC1-R antagonist or an adenylate cyclase inhibitor. Cyclic AMP 54-58 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 29545542-4 2018 In parallel, PACAP-induced PRL promoter activity was negated or inhibited by suppressing cAMP production, inhibiting PKA activity, removal of extracellular Ca2+, VSCC blockade, calmodulin (CaM) antagonism, and inactivation of CaM kinase II. Cyclic AMP 89-93 adenylate cyclase activating polypeptide 1 Mus musculus 13-18 29545542-8 2018 These results suggest that PACAP can stimulate PRL promoter activation by PAC1 mediated functional coupling of the Ca2+/CaM/CaM kinase II cascades with the AC/cAMP/PKA pathway. Cyclic AMP 159-163 adenylate cyclase activating polypeptide 1 Mus musculus 27-32 27046436-4 2016 The pituitary adenylate cyclase-activating polypeptide (PACAP) increases intracellular cAMP level, a second messenger known to stimulate the DIO2 gene; however, its importance in tanycytes is not completely characterized. Cyclic AMP 87-91 adenylate cyclase activating polypeptide 1 Mus musculus 4-54 27046436-4 2016 The pituitary adenylate cyclase-activating polypeptide (PACAP) increases intracellular cAMP level, a second messenger known to stimulate the DIO2 gene; however, its importance in tanycytes is not completely characterized. Cyclic AMP 87-91 adenylate cyclase activating polypeptide 1 Mus musculus 56-61 27046436-11 2016 In conclusion, PACAP is an endogenous regulator of the HPT axis by affecting T3-mediated negative feedback via cAMP-induced D2 expression of tanycytes. Cyclic AMP 111-115 adenylate cyclase activating polypeptide 1 Mus musculus 15-20 24039785-4 2013 We established the activity of these receptors by cAMP accumulation upon induction by PACAP. Cyclic AMP 50-54 adenylate cyclase activating polypeptide 1 Mus musculus 86-91 25303162-1 2015 Pituitary adenylate cyclase-activating polypeptide (PACAP) was originally identified as a hypothalamic activator of cyclic adenosine monophosphate production in pituitary cells. Cyclic AMP 116-146 adenylate cyclase activating polypeptide 1 Mus musculus 0-50 25303162-1 2015 Pituitary adenylate cyclase-activating polypeptide (PACAP) was originally identified as a hypothalamic activator of cyclic adenosine monophosphate production in pituitary cells. Cyclic AMP 116-146 adenylate cyclase activating polypeptide 1 Mus musculus 52-57 23899713-3 2013 PACAP increased the activity of the serum response element (Sre) promoter, a target of extracellular signal-regulated kinase (ERK), as well as the cAMP response element (Cre) promoter in GT1-7 cells overexpressing PAC1R. Cyclic AMP 147-151 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 23899713-4 2013 We also observed ERK phosphorylation and cAMP accumulation upon PACAP stimulation. Cyclic AMP 41-45 adenylate cyclase activating polypeptide 1 Mus musculus 64-69 23899713-10 2013 Our observations show that PACAP increases GnRHR expression and stimulates kisspeptin"s effect on GnRHR expression in association with the cAMP/PKA signaling pathway in GT1-7 cells overexpressing PAC1R. Cyclic AMP 139-143 adenylate cyclase activating polypeptide 1 Mus musculus 27-32 24039785-6 2013 PACAP increased cAMP production within 15 min upon stimulation and targeted the expression and phosphorylation of MAPK (ERK1/2), strengthened by the ERK1/2 phosphorylation being partially or completely abolished by different combinations of PACAP receptors antagonists. Cyclic AMP 16-20 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 24039785-6 2013 PACAP increased cAMP production within 15 min upon stimulation and targeted the expression and phosphorylation of MAPK (ERK1/2), strengthened by the ERK1/2 phosphorylation being partially or completely abolished by different combinations of PACAP receptors antagonists. Cyclic AMP 16-20 adenylate cyclase activating polypeptide 1 Mus musculus 241-246 22001548-1 2012 As an activator of adenylate cyclase, the neuropeptide Pituitary Adenylate Cyclase Activating Peptide (PACAP) impacts levels of cyclic AMP, a key second messenger available in brain cells. Cyclic AMP 128-138 adenylate cyclase activating polypeptide 1 Mus musculus 103-108 22532103-0 2013 Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMP-PKA pathway. Cyclic AMP 91-95 adenylate cyclase activating polypeptide 1 Mus musculus 13-18 22532103-9 2013 CONCLUSION: Our novel findings document the importance of PACAP-mediated cAMP-PKA signaling in hepatic homeostasis and cytoprotection in vivo. Cyclic AMP 73-77 adenylate cyclase activating polypeptide 1 Mus musculus 58-63 23447598-3 2013 Previously, we found that PACAP was an anti-mitogenic signal from embryonic day 13.5 (E13.5) onward both in culture and in vivo and activated cAMP signaling through the short isoform. Cyclic AMP 142-146 adenylate cyclase activating polypeptide 1 Mus musculus 26-31 19496170-0 2009 cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells. Cyclic AMP 0-4 adenylate cyclase activating polypeptide 1 Mus musculus 19-24 20388963-11 2009 Furthermore, rolipram significantly increased cAMP production induced in the isolated stomach by histamine and PACAP. Cyclic AMP 46-50 adenylate cyclase activating polypeptide 1 Mus musculus 111-116 21726625-1 2011 Pituitary adenylate-cyclase activator polypeptide (PACAP), as a consequence of its effect on the elevation of intracellular cAMP level, strongly influences brain development including myelination. Cyclic AMP 124-128 adenylate cyclase activating polypeptide 1 Mus musculus 0-49 21726625-1 2011 Pituitary adenylate-cyclase activator polypeptide (PACAP), as a consequence of its effect on the elevation of intracellular cAMP level, strongly influences brain development including myelination. Cyclic AMP 124-128 adenylate cyclase activating polypeptide 1 Mus musculus 51-56 21388403-7 2011 PACAP-dependent transcriptional stress responses are conveyed through noncanonical cyclic AMP- and calcium-initiated signaling pathways within the HSA circuit. Cyclic AMP 83-93 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 21388403-8 2011 PACAP transcriptional regulation of the HPA axis, in the hypothalamus, is likely to be mediated via canonical cyclic AMP signaling through protein kinase A. Cyclic AMP 110-120 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 19496170-1 2009 The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP), a member of the glucagon/vasoactive intestinal peptide (VIP) superfamily, stimulates cyclic AMP accumulation initiating a variety of biological processes such as: neurotropic actions, immune and pituitary function, learning and memory, catecholamine biosynthesis and regulation of cardiopulmonary function. Cyclic AMP 162-172 adenylate cyclase activating polypeptide 1 Mus musculus 69-74 19496170-5 2009 Consistent with expression of receptor subtype, both PACAP and VIP stimulate cAMP accumulation in a time- and dose-dependent manner with the similar potency in undifferentiated and differentiated cells, while Maxadilan, a specific agonist for PAC1-R, did not. Cyclic AMP 77-81 adenylate cyclase activating polypeptide 1 Mus musculus 53-58 19496170-6 2009 Furthermore, downregulation of VPAC2-R by siRNA completely blocked cAMP response mediated by PACAP and VIP. Cyclic AMP 67-71 adenylate cyclase activating polypeptide 1 Mus musculus 93-98 19496170-7 2009 Importantly, PACAP/VIP as well as forskolin markedly suppressed the induction of alkaline phosphatase mRNA upon differentiation and the pretreatment with 2",5"-dideoxyadenosine, a cAMP inhibitor, restored its inhibitory effect of PACAP. Cyclic AMP 180-184 adenylate cyclase activating polypeptide 1 Mus musculus 13-18 19129676-7 2008 The results revealed that PACAP exerts, in addition to early stimulatory effect on cAMP formation-steroidogenesis, sustained suppressive effect on cell proliferation in TM3 cells by controlling progression of the cell cycle. Cyclic AMP 83-87 adenylate cyclase activating polypeptide 1 Mus musculus 26-31 18579744-3 2008 In addition, we have reported previously that the neurotrophic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) is able to promote astrocyte differentiation of cortical precursors via activation of a cAMP-dependent pathway. Cyclic AMP 218-222 adenylate cyclase activating polypeptide 1 Mus musculus 71-121 18579744-3 2008 In addition, we have reported previously that the neurotrophic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) is able to promote astrocyte differentiation of cortical precursors via activation of a cAMP-dependent pathway. Cyclic AMP 218-222 adenylate cyclase activating polypeptide 1 Mus musculus 123-128 18579744-7 2008 PACAP raises intracellular calcium concentration via a mechanism that requires cAMP, and DREAM-mediated transactivation of the GFAP gene requires the integrity of calcium-binding domains. Cyclic AMP 79-83 adenylate cyclase activating polypeptide 1 Mus musculus 0-5 18579744-10 2008 These results identify the PACAP-cAMP-Ca(2+)-DREAM cascade as a new pathway to activate GFAP gene expression during astrocyte differentiation. Cyclic AMP 33-37 adenylate cyclase activating polypeptide 1 Mus musculus 27-32